News | Stents Carotid | November 18, 2016

Study Supports Clinical Benefit, Utility of CGuard Embolic Prevention System

Results indicate 100 percent procedural success rate in a 30-patient study, with no procedural related complications and zero strokes at six-month follow-up

InspireMD, CGuard embolic protection system, EPS, clinical data, internal carotid artery stenosis, ICA

November 18, 2016 — InspireMD Inc. announced in mid-October the online publication of positive clinical data in a new independent study that evaluated the company’s CGuard embolic protection system (EPS) in patients with symptomatic or high-grade asymptomatic internal carotid artery (ICA) stenosis.

The study, entitled “Clinical Results and Mechanical Properties of the Carotid CGuard Double-Layered Embolic Prevention Stent,” was performed by Prof. Christian Wissgott, M.D. It was published in the Journal of Endovascular Therapy online-ahead-of-print and is available digitally on the journal’s OnlineFirst website section. The OnlineFirst section also includes an accompanying editorial written by Prof. Piotr Musialek, M.D., entitled “Carotid Artery Revascularization for Stroke Prevention: A New Era,” which underscores the use of CGuard EPS as a novel approach to potentially reducing the risk of stroke by avoiding the risks associated with conventional carotid stenting.

Wissgott, assistant director at Westkustenklinikum, Heide, Germany, independently evaluated CGuard properties against other carotid stents and conducted a study in 30 consecutive patients with ICA disease. The average stenosis of the treated arteries was 84 percent with a mean lesion length of 17 mm. The majority of the patients (83 percent) had symptomatic disease. Patients were followed for six months post-procedure and were assessed using a number of variables, including stroke, change in modified Rankin Scale (mRS), CGuard EPS patency, and new ipsilateral lesions as measured by diffusion weighted-magnetic resonance imaging (DW-MRI). Key findings from the six-month study included:

  • One hundred percent success in implanting the CGuard EPS;
  • No peri- or post-procedural complications;
  • No deaths, major adverse events, minor or major strokes, or new neurologic symptoms during the six months following the procedure;
  • Modified Rankin Scale improved for the symptomatic patients from 1.56 prior to the procedure to 0 afterwards;
  • All vessels treated with the CGuard system remained patent (open) at six months; and
  • DW-MRI performed in 19 of 30 patients found no new ipsilateral lesions after 30 days and after six months compared with the baseline DW-MRI studies.

For more information: www.jet.sagepub.com

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init